Is colchicine therapy effective in all patients with secondary amyloidosis?

References

• Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29:77–86
   PubMed Web of Science ®Google Scholar
• Oner A, Erdoğan O, Demircin G, et al. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18:521–526
   PubMed Web of Science ®Google Scholar
• Sevoyan MK, Sarkisian TF, Beglaryan AA, et al. Prevention of amyloidosis in familial Mediterranean fever with colchicine: a case-control study in Armenia. Med Princ Pract. 2009;18:441–446
   PubMed Web of Science ®Google Scholar
• Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001–1005
   PubMed Web of Science ®Google Scholar
• Cakar N, Yalçinkaya F, Ozkaya N, et al. Familial Mediterranean fever associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol. 2001;19:63–67
   Google Scholar
• Kaaroud H, Boubaker K, Béji S, et al. Renal amyloidosis followed more than 5 years: report of 12 cases. Transplant Proc. 2004;36:1796–1798
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
   PubMed Web of Science ®Google Scholar
• Saatçi U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997;156:619–623
   PubMed Web of Science ®Google Scholar
• Ravid M, Robson M, Kedar I. Prolonged colchicine treatment in four patients with amyloidosis. Ann Intern Med. 1977;87:568–570
   Google Scholar
• Simşek B, Işlek I, Simşek T, Küçüködük S, Cengiz K. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant. 2000;15:281–282
   PubMedGoogle Scholar
• Rozenbaum M, Rosner I. Regression of amyloidosis with colchicine in familial Mediterranean fever in an Ashkenazi patient. Clin Exp Rheumatol. 1995;13:126
   Google Scholar
• Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994;37:1804–1811
   PubMed Web of Science ®Google Scholar
• Sarkissian A, Papazian M, Sanamyan A, Leumann E. Colchicine in the treatment of renal amyloidosis secondary to familial Mediterranean fever. Nephrol Dial Transplant. 2000;15:1098
   Google Scholar
• Bergesio F, Ciciani MA, Santostefano M, et al. Renal involvement in systemic amyloidosis – an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22:1608–1618
   PubMed Web of Science ®Google Scholar
• Immonen K, Finne P, Hakala M, Kautiainen H, Pettersson T, Grönhagen-Riska C. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases data from the Finnish national registry for kidney diseases. J Rheumatol. 2008;35:1334–1338
   PubMed Web of Science ®Google Scholar
• Teilum G. Pathogenesis of amyloidosis. Acta Pathol Microbiol Scand. 1964;61:21–45
   PubMedGoogle Scholar
• Sipe JD, McAdam KP, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest. 1978;38:110–114
   PubMed Web of Science ®Google Scholar
• Shirahama T, Cohen AS. Redistribution of amyloid deposits. Am J Pathol. 1980;99:539–550
   PubMed Web of Science ®Google Scholar
• Kuczynski M. Further contributions to the principle of amyloid. Klin Wochenschr. 1923;2:2193–2195
   Google Scholar
• Hawkins PN, Pepys MB. A primed state exists in vivo following histological regression of amyloidosis. Clin Exp Immunol. 1990;81:325–328
   PubMed Web of Science ®Google Scholar
• Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012;142:13580
   PubMed Web of Science ®Google Scholar
• Nowak B, Jeka S, Wiland P, Szechiński J. Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. Joint Bone Spine. 2009;76:217–219
   Google Scholar
• Smith GR, Tymms KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Internal Med J. 2004;34:570–572
   Google Scholar
• Tweezer-Zaks N, Langevitz P, Livneh A. Long-term followup needed to define role of infliximab in treatment of renal amyloidosis: comment on the case report by Elkayam et al. Arthritis Rheum. 2003;48:3298–3299
   Google Scholar